Pharma & Biotech Insights, Interviews & Features
Biotechnology
14 November 2024 14 November 2024
Today's issue
Refine Search
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Pharmaceutical
The Russian government has adopted a new method for determining the prices for vital and essential drugs, according to an official spokesman of Russian Minister of Health Veronika Skvortsova, reports The Pharma Letter’s local correspondent. 13 December 2018
Pharmaceutical
Russian drugmaker Polysan will invest about 4 billion roubles (~$60 million) in the establishment of full-cycle production of a drug from German pharma major Bayer, according to the company, reports The Pharma Letter’s local correspondent. 13 December 2018
Generics
Activity in the pharma sector is rife in India, with mergers and acquisition deal values doubling given revived domestic and cross-border deal activity. Technology in the form of Artificial Intelligence and Big Data has also come to the aid of the pharmaceutical industry, reports The Pharma Letter’s India correspondent. 12 December 2018
Pharmaceutical
Mark Timney has been named as the new chief executive of The Medicines Company. 12 December 2018
Biotechnology
Japanese biotech firm Sosei Group today announced that its board of directors, at a meeting held on December 11, 2018, approved a change in its president and chief executive (CEO). 12 December 2018
Biosimilars
Although biosimilars have taken off in Europe, they have yet to gain traction in the USA, writes Anne Runyan, senior consultant of market access at MKO Global Partners, in an Expert View on the topic. 11 December 2018
Pharmaceutical
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has named David Ricks, the chairman and chief executive of US pharma major Eli Lilly, as its new president. 11 December 2018
Pharmaceutical
Adam Schechter, president of Global Human Health (GHH) at US pharma giant Merck & Co, is stepping down from his current position as of December 31, 2018, and will be shifting to an advisory capacity to the chief executive. 11 December 2018
Biotechnology
Following the previously-announced plans of John Milligan to step down from the top post by year-end, US biotech major Gilead Sciences has named Daniel O'Day as chairman and chief executive, effective March 1, 2019. 10 December 2018
Pharmaceutical
Daniel O'Day, chief executive of Roche Pharmaceuticals and member of the Roche corporate executive committee, will be stepping down from his role as of December 31, 2018. 10 December 2018
Pharmaceutical
An exclusive Expert View column written for The Pharma Letter by Thomas Cueni, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) director general and co-chair of the APEC Biopharmaceutical Working Group on Ethics. 6 December 2018
Pharmaceutical
Drug-making is sometimes pictured as one of the last surviving “traditional” industries, successfully resisting waves of change that have overtaken other businesses. 5 December 2018
Pharmaceutical
Leading Russian pharmaceutical companies have called on the national government to provide additional support that will be used for the launch of full cycle production and the increase of exports, according to recent statements of producers and some senior officials of the Russian Ministry of Health, reports The Pharma Letter’s local correspondent. 3 December 2018
Pharmaceutical
Leading Russian and foreign drugmakers operating in Russia will be able to launch their drugs more quickly in the local pharmaceutical market, thanks to the recent amendments approved by the Council of Federation, the 3 December 2018
Pharmaceutical
A look at what's coming up at one of pharma's most important conferences. 30 November 2018
Pharmaceutical
Ireland-headquartered pioneering inflammasone company Inflazome has announced the appointment of Dr Thomas Jung as its chief medical officer. 30 November 2018
Generics
Netherlands-headquartered Mylan’s (Nasdaq: MYL) flagship oral solids facility getting a US Food and Drug Administration warning letter is being viewed as an advantage Indian drug majors, reports The Pharma Letter’s India correspondent. 30 November 2018
Biotechnology
Charlotte Tillett, partner, and Emily Hocken, trainee, at Stevens & Bolton, offer an Expert View on the significance of the UK Supreme Court ruling in Warner-Lambert (WL) v Generics relating to WL’s best-selling pain relief drug, Lyrica (pregabalin). 28 November 2018
Pharmaceutical
Marco Cerato has left privately-held Swiss drugmaker Helsinn to join the Mundipharma network of independent associated companies. 28 November 2018
Biotechnology
Israel and USA-based biotech Anchiano Therapeutics today announced the appointment of David Kerstein, as the company’s new chief medical officer (CMO). 27 November 2018
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze